Tislelizumab for Gastric Cancer
This trial is testing a new cancer drug against placebo to see if it is more effective at treating gastric or gastroesophageal junction cancer.
- Gastric Cancer
Study ObjectivesOutcome measures can provide a clearer picture of what you can expect from a treatment.
Side effects dataFrom 2021 Phase 2 trial • 113 Patients • NCT04004221
Awards & Highlights
Find a site
Who is running the clinical trial?
Frequently Asked Questions
Is Tislelizumab likely to cause any negative side effects in patients?
"Tislelizumab's safety is estimated to be a 3. This assessment comes from the fact that Tislelizumab is in Phase 3 of clinical trials. At this stage, there is already some data supporting efficacy and multiple rounds of data supporting safety."
Where are patients being asked to participate in this experiment?
"There are 7 locations available for this study, which include Reading Hospital in West Reading, Fox Chase Cancer Center in Philadelphia, and University of California Davis Health System in Sacramento."
What do we know about Tislelizumab from other research?
"As of right now, there are a whopping 1326 different clinical trials underway that involve Tislelizumab. That being said, 461 of those studies are still in Phase 3. The majority of these research programs are based out of Guangzhou, Guangdong; however, there are 61814 locations worldwide where Tislelizumab is being trialed as a potential treatment option."
Are there any spots left for new participants in this scientific experiment?
"No, the trial is not currently recruiting patients. The last update on clinicaltrials.gov was on August 25th, 2022 and indicated that the study is not presently looking for new candidates. There are 2309 other trials you may be eligible for."